Penicillin allergy status and its effect on antibiotic prescribing, patient outcomes and antimicrobial resistance (ALABAMA): protocol for a multicentre, parallel-arm, open-label, randomised pragmatic trial

Kelsey Fiona Armitage, Catherine E Porter, Shadia Ahmed, Johannah Cook, Jenny Boards, Emily Bongard, Christopher C Butler, Kate Corfield, Mina Davoudianfar, Ushma Galal, Philip Howard, Ruben Mujica-Mota, Razan Saman, Marta Santillo, Sinisa Savic, Bethany Shinkins, Sarah Tonkin-Crine, Marta Wanat, Robert M West, Ly-Mee Yu, Sue Pavitt, Jonathan A T Sandoe

ABSTRACT

Introduction Incorrect penicillin allergy records are recognised as an important barrier to the safe treatment of infection and affect an estimated 2.7 million people in England. Penicillin allergy records are associated with worse health outcome and antimicrobial resistance. The ALergy AntiBiotics And Microbial resistAnce (ALABAMA) trial aims to determine if an intervention package, centred around a penicillin allergy assessment pathway (PAAP) initiated in primary care, is safe and effective in improving patient health outcomes and antibiotic prescribing.

Methods and analysis The ALABAMA trial is a multicentre, parallel-arm, open-label, randomised pragmatic trial with a nested pilot study. Adults (≥18 years) with a penicillin allergy record and who have received antibiotics in the previous 24 months will be eligible for participation. Between 1592 and 2090 participants will be recruited from participating National Health Service general practices in England. Participants will be randomised to either usual care or intervention to undergo a pre-emptive PAAP using a 1:1 allocation ratio. The primary outcome measure is the percentage of treatment response failures within 28 days of an index prescription. 2090 and 1592 participants are estimated to provide 90% and 80% power, respectively, to detect a clinically important absolute difference of 7.9% in primary outcome at 1 year between groups. The trial includes a mixed-methods process evaluation and cost-effectiveness evaluation.

Ethics and dissemination This trial has been approved by London Bridge Research Ethics Committee (ref: 19/LO/0176). It will be conducted in compliance with Good Clinical Practice guidelines according to the Declaration of Helsinki. Informed consent will be obtained from all subjects involved in the study. The primary trial results will be submitted for publication to a international, peer-reviewed journal.

INTRODUCTION

A record of penicillin allergy (PEN allergy) in a patient’s health record has a marked effect on antibiotic prescribing; both an increase in total use and a radical change in the agents selected.1,2 In primary care patients, the presence of a PEN allergy record has been associated with higher rates of treatment failure, higher mortality, *Clostridioides difficile* infection and antimicrobial resistance (AMR) in...
the form of methicillin resistant (also known as meticillin-resistant) *Staphylococcus aureus*. PEN allergy records are common and arise either because of genuine allergy symptoms during a course of treatment or, more often, because side effects and symptoms related to the index infection are mislabelled as allergies. In the UK, PEN allergy prevalence is approximately 6%. However, fewer than one in 10 patients with a PEN allergy record are truly allergic after formal assessment. Consequently, an estimated 2.7 million people in the UK are potentially prevented from accessing highly effective penicillin due to an incorrect PEN allergy record.

Macrolide, tetracycline, cephalosporin, quinolone and clindamycin prescribing are all more common in primary care patients with a record of PEN allergy compared with those without, and antibiotic prescriptions are almost twice as frequent in patients with a PEN allergy record. Evidence from USA and elsewhere suggests that antibiotic allergies affect health outcomes, and increase mortality, length of stay and costs. PEN allergy records are also associated with AMR; evidence from the UK and USA suggests that patients with a penicillin allergy record are more likely to acquire multidrug resistant bacteria, including methicillin-resistant *Staphylococcus aureus* (MRSA). Preliminary investigations of 2.3 million adult primary care patients found that a lack of response to treatment and MRSA were significantly more common in patients with a PEN allergy record. The 2019 WHO AWARe classification groups antibiotics into three stewardship categories: ‘Access, Watch and Reserve’, and aims to promote use of Access antibiotics in order to combat AMR. Patients with PEN allergy are more likely to be prescribed antibiotics belonging to the Watch and Reserve groups which have a higher propensity to drive AMR.

The gold standard test with which to establish tolerance to penicillins is a drug provocation test (which includes oral challenge testing), but previous UK and US guidelines have advised that patients should first be skin tested, using prick or intradermal tests, or both. The latest US guidelines now recommends for ‘low risk’ historical penicillin allergic patients, direct oral challenge without preceding skin testing. Assessment of patients with PEN allergy in specialist clinics is provided within the National Health Service (NHS) and is often performed over at least two clinic visits; the first, to undertake history and perform skin testing; the second to assess reactions and undertake a penicillin oral challenge test, followed by communication of results. Currently, most patients who are eligible to undergo PEN allergy assessment are not offered the service because of a lack of testing capacity. One-stop allergy testing offers the potential to improve allergy testing capacity. This currently differs from UK standard and European guidelines in that it offers patients who have been assessed as ‘low risk’ of true allergy an abbreviated test consisting of direct oral challenge, i.e. with no preceding skin tests, and is consistent with more recent guidelines for non-allergists. The direct oral challenge approach is already used routinely for children in the UK and several studies have demonstrated safety and efficacy in adults. A recent systematic review has found that direct oral challenge testing by non-allergists is safe and reported an incidence of 1% (95% CI, 0% to 2%) of immediate or delayed reactions in a pooled analysis of 69 studies. Patients whose histories are not clearly low risk still need to undergo skin testing, and only proceed to oral challenge if this is negative.

The Allergy Antibiotics And Microbial resistance (ALABAMA) trial (full title: penicillin allergy status and its effect on antibiotic prescribing, patient outcomes and AMR) will evaluate participants randomised to either usual care or to receive ‘Penicillin Allergy Assessment Pathway’ (PAAP). PAAP is a complex intervention, incorporating one-stop allergy testing and appropriate delabeling of electronic health records. It will evaluate if PAAP is safe and effective in improving patient health outcomes, influencing antibiotic prescribing and supporting healthcare implementation. ALABAMA is the first randomised controlled trial to our knowledge that looks at adult PEN allergy testing and delabelling with a primary health outcome.

**METHODS AND ANALYSIS**

**Study design**

ALABAMA is a multicentre, two parallel-arm, open-label, individually randomised pragmatic trial with a nested pilot study and embedded process evaluation and cost-effectiveness evaluation. The protocol for ALABAMA was developed according to the Standard Protocol Items Recommendations for Interventional Trials guidelines. A nested pilot was conducted from December 2018 to July 2020 to determine the safety, feasibility, acceptability and practicality of the ALABAMA trial. This included a ‘stop/go’ assessment criteria which was based on feasibility, recruitment and safety.

The main ALABAMA trial evaluates a complex intervention, designed according to the Medical Research Council guidelines. The complex intervention is collectively referred to as the ‘PAAP’. This comprises: (1) an efficient direct referral for a ‘one-stop’ single appointment for an allergy assessment and testing; (2) appropriate guidance for clinicians to refer patients for PEN allergy testing and instruction on how to delabel, that is, update allergy status in participants’ electronic health records appropriately and (3) information for participants to encourage attendance for testing and information pretesting to distinguish side effects (eg, diarrhoea) from true allergic reactions. The development of the physician and participant behavioural intervention component is reported elsewhere.

Enrolment started at the first general practice (GP) site as part of the feasibility study in October 2019 and recruitment is expected to finalise in 2023.

**Participants and eligibility**

Between 1592 and 2090 participants will be recruited from participating NHS GPs in England. The inclusion
and exclusion criteria are described in table 1. Potential participants who meet the eligibility criteria will be identified during a search of electronic health records at their GP. The electronic search criteria have been developed centrally by the research team in partnership with The Phoenix Partnership (TPP), healthcare technology company, and made available for running locally on SystmOne (an electronic health record system used in primary care that was developed by TPP), thus participating GPs must be using SystmOne. Potentially eligible patients will then be sent an invitation letter.

Patients interested in taking part will return an expression of interest form to the trial team by post, phone or email or by following a link to add their details to an online secure database. They will then be telephoned and booked into either a face to face or telephone appointment with their GP (or a delegated member of staff) at a time that is convenient to them. The GP, and delegates, will have received full protocol training and the GP will take on the role of Principal Investigator at site. The GP, or a delegated member of staff, will confirm the patient’s eligibility and obtain their consent to participate in the trial (see online supplemental appendices 1 and 2). Participants must meet the inclusion criteria and have none of the exclusion criteria.

Patient and public involvement

AMR and antimicrobial allergy lack patient groups/hospital networks/local charities to draw on for patient and public involvement and engagement (PPIE), necessitating us building a specific ALABAMA PPIE-Allergy Forum (PPIE-AF) to contribute to the research design, execution and dissemination strategy. The PPIE-AF comprises people with previous PEN allergies, including those whose record has been overturned and can now receive penicillins. It also includes those with self-reported (unsubstantiated) PEN allergy.

Our research adopts a codesign approach where our PPIE-AF contributors input to ensure we designed a trial that is patient-centred with the shared goal to maximise improved NHS care and patient outcomes. Specifically, the trial was designed to be inclusive and to minimise long/multiple hospital visits during the penicillin allergy testing (PAT). This is therefore the first trial designed as a ‘one stop’ efficient allergy assessment for low risk individuals. The guidance to participants about delabelling

<table>
<thead>
<tr>
<th>Inclusion</th>
<th>Exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient is willing and able to give informed consent for participation in the trial</td>
<td>Life expectancy estimated &lt;1 year by GP</td>
</tr>
<tr>
<td>Male or female, aged 18 years or above</td>
<td>Unable to attend immunology clinic</td>
</tr>
<tr>
<td>Current penicillin allergy (or sensitivity) record of any kind in their electronic health record</td>
<td>Unsuitable for entry into testing pathway because:</td>
</tr>
<tr>
<td>Prescribed systemic antibiotics in the previous 24 months</td>
<td>– Allergy history consistent with anaphylaxis to penicillin</td>
</tr>
<tr>
<td>– History of toxic epidermal necrolysis, Stevens-Johnson syndrome, Drug reaction with eosinophilia and systemic symptoms (DRESS) or any severe rash which blistered or needed hospital treatment, and acute generalised exanthematous pustulosis precipitated by a penicillin</td>
<td></td>
</tr>
<tr>
<td>– Has been formally tested for penicillin allergy in the past and been found to be penicillin allergic</td>
<td></td>
</tr>
<tr>
<td>– History of brittle/severe asthma or has had a course of steroids in the past 3 months for asthma or unstable coronary artery disease, or severe/poorly controlled skin conditions</td>
<td></td>
</tr>
<tr>
<td>– Considered unsuitable for trial participation by the GP for example, because of chaotic lifestyle</td>
<td></td>
</tr>
<tr>
<td>– Pregnant</td>
<td></td>
</tr>
<tr>
<td>– Breastfeeding mothers</td>
<td></td>
</tr>
<tr>
<td>– Currently taking beta blocker medication, and unable to temporarily withhold these on the day of penicillin allergy testing</td>
<td></td>
</tr>
<tr>
<td>– Currently taking (or recently taken) systemic steroids and unable to stop these for 10 days pretesting</td>
<td></td>
</tr>
<tr>
<td>– Currently taking antihistamines and unable to temporarily withhold these for 72 hours pretesting</td>
<td></td>
</tr>
<tr>
<td>– GPs may also want to exclude vulnerable patients who are deemed to be unsuitable to participate for other reasons such as, but not limited to, terminal illness, reliability, mental illness, learning difficulties, anxiety, other family circumstances.</td>
<td></td>
</tr>
</tbody>
</table>

Note 1, patients with a penicillin allergy record and a recent penicillin prescription would still be eligible because their allergy status will need assessment and records correcting if necessary. 

Note 2, patients who have been formally tested for penicillin allergy in the past and been found not to be penicillin allergic but still have a medical record indicating a penicillin allergy are eligible for the trial. 

Note 3, Patients who are currently taking medicines with antihistamine properties that cannot be temporarily withheld, or patients with isolated dermographism, may still be eligible to take part but will need to be discussed with the research team prior to consent.

GP, general practice.
also facilitates ease of future NHS implementation and patient uptake of PAT.

PPIE-AF members have been engaged in both the nested pilot and main trial—they reviewed and provided input into the protocol development and the ethics submission. They contributed to the design of the qualitative enquiry and its ethics submission, bringing their lived experience to shape the interview topic guide. They guided the need to develop educational material to support patients if their PEN allergy status is changed.

PPIE-AF members have ensured that our inclusion criteria are broad and include patient groups that are high antimicrobial users. The research team incorporated their views that limiting eligibility to a single group of patients (eg, only those with chronic obstructive pulmonary disease) would limit the applicability of findings and thus potential benefit in patients across health conditions and age groups, especially those over 65 years, who probably have the highest rate of inappropriate PEN allergy labels and who may benefit from testing. PPIE-AF members have ensured that the trial material is understandable and appropriate for patients considering participation and that the trial intervention itself is not too onerous and has a clear patient-centred approach. The PPIE-AF have great ambitions for disseminating using a proven Theatre of Debate involvement to make our research findings accessible to all based on our similar award winning application in NIHR COVID and Me.

**SystmOne and ALABAMA unit**

SystmOne is one of the major electronic health record systems used in primary care in the UK, which was developed by TPP, Leeds, UK, a health technology company. Enrolment of GPs into the ALABAMA trial requires that they use SystmOne as their health record system. Functionality of SystmOne allows the participating GPs to share health records of consented participant and to direct referrals for allergy testing, this sharing functionality is referred to as the ‘ALABAMA unit’. Delegated members of the ALABAMA trial team can gain access to the ALABAMA unit and can then view consented participants’ medical records and monitor antibiotic prescribing activity by running bespoke reports within the ALABAMA unit. Participants’ electronic health records will not be altered by the trial team but selected information, alerts, GP tasks and bespoke data reports can be generated, facilitating trial data capture. For example, the ALABAMA unit allows the GP practice to run a bespoke report of potentially eligible patients, allows the research team to track the delabelling process of ALABAMA participants confirmed as PEN allergy negative and enables the follow-up of participants given an antibiotic in the 12 month period following randomisation.

**Randomisation**

Randomisation will be performed using Sortition (an online randomisation system developed by the Primary Care Clinical Trials Unit of University of Oxford). Participants will be randomised to either usual care or the intervention arm using an allocation ratio of 1:1. Allocation will be minimised by GP, age, number of antibiotic prescriptions in the 24 months (12 months for participants recruited to nested pilot) prior to randomisation, and number of Quality and Outcomes Framework (QOF) registered diseases to ensure balance of allocation of these baseline covariates. Both the participants and the recruiter will know which arm they have been randomised into. The trial statistician will remain blinded to treatment allocation when performing the final analysis.

**Data recording and record keeping**

The OpenClinica system will incorporate data entry and validation rules to reduce data entry errors, and management functionalities to facilitate auditing and data quality assurance. Data protection requirements will be embedded into the design of the web-based system and enforced by best practice trial management procedures. The Clinical Data Manager will oversee the process of electronic data validation and manual listings, sending out Data Clarification Forms when required and following these up until the queries are resolved.

The trial staff will ensure that the participants’ anonymity is maintained. The participants will be identified only by a participant ID number on all trial documents and any electronic database, with the exception of the CRF, where participant initials may be added. All documents will be stored securely and only accessible by trial staff and authorised personnel. The trial will comply with the Data Protection Act 2018, which requires data to be anonymised as soon as it is practical to do so.

**Trial outcomes**

**Primary outcome**

The primary objective is to determine whether the intervention package is clinically effective in improving patient health outcomes. This will be measured using ‘treatment response failure’ rate which is defined as: representation with worsening or non-resolving or new symptoms following treatment with an antibiotic up to 28 days after initial antibiotic prescription (including re-prescription of antibiotic within 28 days of an index prescription) for predefined infections over at least 1 year subsequent to randomisation. These predefined infections are ones managed in the community for which a penicillin would be recommended as first-line therapy (see online supplemental appendix A). Assignment of antibiotic prescriptions as primary events will be checked by clinical members of the research team blinded to both the trial allocation and outcome of the event.

**Secondary outcomes**

Secondary outcomes are:

1. Effects of PAAP duration on symptoms rated ‘moderately bad’ or worse by patients after antibiotic treatment.
2. Effects of PAAP on antibiotic use (total duration, number of courses, defined daily doses and an equivalent analysis by antibiotics class, eg, penicillins).
3. Effects of PAAP on number of hospital admissions and length of hospital stays.
4. Effects of PAAP on mortality rates.
5. Effects of PAAP on number of patients with MRSA infection/colonisation.
6. Effects of PAAP on number of patients with *C. difficile* infection.
7. Cost effectiveness for the PAAP intervention compared with usual care through self-reported health-related quality of life outcomes.

The process evaluation will explore patient and clinician views and experiences of the PAAP, trial procedures and implications on delabelling on subsequent antibiotic prescribing and penicillin use through interviews. We will measure the influences on patient behaviour change through questionnaires.

**Trial procedures**

Participant screening, eligibility checks, and consent will be carried out by GPs or appropriately trained authorised staff delegated to do this on behalf of the GP. Subsequent trial procedures are carried out by the ALABAMA trial team, who will communicate PAT results to GPs.

**Study intervention package**

The intervention package includes the PAAP and support materials for clinicians and participants. 

On entry to the study, practices will receive site training and support materials for clinicians to help them in discussing and referring participants to the PAAP. Clinicians will receive an information leaflet (titled *Penicillin Allergy Testing: Information for general practice*) that includes evidence-based information to increase knowledge about PAT and motivation to refer participants for a PAT and prescribe penicillin after a negative PAT result. They will also receive training in making changes to the electronic health record when a participant receives a negative allergy test result.

The central component of the study intervention package is the PAT which will be carried out in three stages:
- Stage 1: in primary care—clinical History.
- Stage 2: skin testing in hospital clinic (this may not be needed for all participants, see figure 1 and online supplemental appendix 3)
- Stage 3: Oral Challenge Test in hospital clinic/followed by subsequent doses at home, see online supplemental appendix 4)

Stage 2, if needed, and stage 3 are performed together during half-a-day clinic visit. If there is no initial reaction

![Testing strategy flow chart](image)

**Figure 1** The ALergy AntiBiotics And Microbial resistance (ALABAMA) trial penicillin allergy testing (PAT) strategy.
in clinic, the participant will continue the oral challenge test by completing 3 days oral antibiotics at home. **Figure 1** shows the PAT flow.

All participants in the intervention arm will be posted a pretest intervention leaflet (titled ‘Penicillin Allergy Testing: going for a test’) prior to their PAT appointment to inform them about incorrect allergy records, how they may benefit from having a PAT and what the test involves.

On completion of PAT, practices will be informed of the test result and instructed to update the participant’s electronic health records accordingly. Entry of the PAT result codes into the participant’s electronic health record activates additional behaviour change materials: pop ups that appear when a GP prescribes antibiotics for a trial participant to remind them of a change to PEN allergy records, if appropriate (**figure 2**).

Participants will receive an allergy test result letter. If they have tested negative, they will receive a second booklet (titled *Penicillin Allergy Testing: a negative test result*) and an Intervention Card. The booklet informs

---

**Figure 2** ALABAMA flow diagram for penicillin allergy assessment pathway (PAAP). ALABAMA, ALLergy AntiBIotics And Microbial resistAnce; GP, general practice; PAT, penicillin allergy test; CRF, case report form.
participants about the reliability of the test results and consequences of a negative test result. The intervention card is a laminated credit card-sized card that says which test the participant has had and confirms the negative allergy result.

The study comparator is usual care with subsequent monitoring for antibiotic prescriptions and follow-up for trial outcomes as determined by the clinical indication for antibiotics. Usual care in this context means antibiotics prescribed by their general practitioner according to routine clinical practice.

**Symptom diary and questionnaires**

- **Symptom diary**—participants will be asked to complete a symptom diary when they receive an antibiotic for a predefined list of infections in the 12 month period from randomisation. Information collected will include the predominant presenting symptoms, symptom severity, antibiotic consumption and any side effects. The diary will be completed for 28 days or until the participant’s symptoms are a ‘slight problem’ or less (scoring 2 and below) and they have stopped their course of antibiotics. Participant diaries will either be recorded on paper case report forms (CRFs) or directly into the Research Electronic Data Capture (REDCap) database.

- **Patient allergy belief questionnaire**—participants will be asked to complete this at baseline and if applicable 28–30 days after completing the PAAP.

- **EQ-5D-5L questionnaire**—participants will be asked to complete this at baseline, 12 months after randomisation and, if applicable, 28–30 days after any GP appointment where an antibiotic was prescribed for one of the predefined infections.

**Linkage with NHS Digital**

The SystmOne ALABAMA unit will remain in existence for 10 years after the close of the trial to support an evaluation of long-term outcomes. Participants will have their electronic health record interrogated via linkage with NHS Digital for data on hospital admissions (Hospital Episode Statistics, HES data), details of antibiotic prescriptions during their admission (GP notes review and secondary care notes review) and mortality data (Office for National Statistics, ONS data). Participants will be consented for this as part of the current ALABAMA trial consent process.

**Safety**

PEN allergy testing is routinely carried out in the NHS and is known to carry a very small risk of anaphylaxis and death. To minimise this risk for participants undergoing the pre-emptive PAT, any participant with a prior history suggestive of anaphylaxis or a previous serious reaction to penicillin will be excluded.

Telephone calls by the trial team at 4–6 days and 28–30 days after PAT will collect information on adverse events (AEs) and serious adverse events (SAEs) associated with PAAP.

AEs and SAEs occurring up to 28 days after an antibiotic prescription from their general practitioner for any predefined infections will be captured through the participant diary and telephone calls by the research team 2–4 days and 28–30 days after the start of an antibiotic prescription. We will capture any AEs that result in a change of antibiotic prescription through the safety review telephone calls and/or notes review.

All SAEs identified during the ALABAMA trial will be assessed for their relatedness to PAAP or antibiotic prescriptions for any of the predefined infections. Anaphylaxis to an antibiotic will be considered an SAE as part of the ALABAMA trial.

Participants in the nested pilot study were also be called monthly for 4 months to assess any safety events. If not captured through the telephone calls, we will collect any other SAE by notes review, HES and mortality data, at month 12.

**Mixed-methods process evaluation**

The mixed-methods process evaluation will include a patient questionnaire (see questionnaires, and semistructured telephone interviews with patients and clinicians). Participants will be asked to complete an allergy belief questionnaire at baseline and, if applicable, 28–30 days after the PAAP.

Purposive sampling will be used to identify a subset of clinicians who will be invited to take part in an interview at the end of the trial to discuss their experiences.

A subset of patient participants will be interviewed once they have completed the PAAP and received their allergy test result to understand their experiences and also for those participants who have received subsequent antibiotic prescriptions following delabelling; this will include those delabelled but refusing penicillin. Participants and clinicians invited to take part in telephone interviews will be provided with patient information sheets and Informed Consent Forms specific to the qualitative component of the process evaluation.

**Statistical analysis**

**Sample size calculation**

A total sample size of 2090 or 1592 participants (1045 or 791 per trial arm, respectively) will provide 90% or 80% power, respectively, to detect a clinically important absolute difference of 7.9% in prescription rate (used as surrogate for treatment response failure) at 1 year between groups at 5% level of significance (two-sided). We plan to recruit 2090 but will fall back on 1592 if recruitment is challenging, as recruitment has commenced during the COVID-19 pandemic and will continue in the postpandemic climate. The sample size has been adjusted assuming that only 50% of participants will require at least one prescription within 1 year from randomisation and allowing for 10% dropout. The first 96 participants of the total will comprise the sample for the nested pilot study.
Primary and secondary outcomes

An intention-to-treat analysis will be conducted for the primary outcome and will include all randomised participants irrespective of what treatment they actually receive. Analysis for the primary outcome, that is, ‘treatment response failure’, will be analysed using a generalised linear mixed-effects model specifying a Binomial distribution with a log link function. GP site will be included in the model as a random effect while relevant baseline covariates and other minimisation factors will be treated as fixed effects. A similar approach will be used for other binary secondary outcomes, while continuous outcomes will be analysed using linear mixed-effects models. Appropriate regression models (such as Poisson regression, Hurdle models etc) will be used for the analysis of count outcomes.

All data will be included in the analysis as far as possible, though there will inevitably be the problem of missing data due to withdrawal, loss to follow-up or non-response questionnaire items. Missing data will be reported, with reasons where available, and the missing data mechanism explored. Sensitivity analysis using imputation methods, such as multiple imputation for data missing at random mechanism, will be considered.

Mixed-methods process evaluation analysis

Descriptive statistics (frequencies and percentages) will be used to summarise responses to questionnaire data.

Data from interviews with clinicians and participants will be analysed using thematic analysis taking an inductive approach. NVivo software will be used to assist with the organisation of data. A thematic framework will be used to chart data across all interviews and will aid comparisons between participants. To further make sense of the data, we will draw in our analysis on behaviour changes theories to facilitate implementation planning.

Cost-effectiveness analysis

A within-trial economic evaluation will estimate the effect on quality of life, costs and incremental cost per quality-adjusted life year (QALY) gained for PAAP versus usual care from the perspective of the NHS and Personal Social Services. The analysis will use trial data collected up to 12 months follow-up post randomisation.

Costs for delivering the PAAP intervention will be measured as part of the trial and the costs of delivering usual care will be calculated based on resource use collected in the trial and unit costs from the published literature. Primary and secondary healthcare service use will be estimated, respectively, from SystmOne electronic records and the linked individual participant HES Health Resource Group (HRG) data. Prescribing data in secondary care will be obtained by the trial team through hand searching of participants’ health records in the lead secondary care centre and other centres when possible or by accessing electronic prescribing systems, if available. Healthcare service costs will be estimated by valuing primary or community care service use using unit costs from published sources, use of medications with list prices from the British National Formulary and HRG unit costs from NHS Reference Costs. QALYs will be calculated using area under the curve interpolations between baseline and 12 month EQ-5D-5L utility data collected in the trial and linked ONS mortality data over the first year after randomisation. No discounting will be applied to costs and QALYs and incremental costs per QALY gained as the time horizon will be limited to 12 months.

Costs will be analysed using generalised linear models with a gamma family and log link to account for skewness, and adjust for GP, age, number of antibiotic prescriptions in the 12 months prior to randomisation and number of QOF registered diseases, as well as baseline EQ-5D-5L score. A similar approach will be applied to analyse QALYs, based on parametric survival models and predicted utility differences between trial arms.

Missing data will be imputed using established methods. Results will be presented in terms of incremental cost per QALY gained and cost per treatment failure avoided at 12 months. Sampling uncertainty will be analysed using the bootstrap method and joint uncertainty in costs and QALYs will be analysed using cost-effectiveness acceptability curves. Sensitivity analyses will explore variations in key cost and QALY assumptions, including interpolation of utility scores from baseline to 12 month data collection points, disutilities associated with AEs and joint parametric distributions used to model costs and QALYs.

ETHICS AND DISSEMINATION

This trial is in compliance with the principles of the Declaration of Helsinki and Good Clinical Practice. Research Ethic Committee (REC) approval was granted by the NRES Committee London Bridge (ref: 19/LO/0176). The Investigator will submit and, where necessary, obtain approval from the above parties for all substantial amendments to the original approved documents.

Informed consent will be obtained from all subjects involved in study.

An independent Data Monitoring Committee (DMC) will review efficacy and safety data by treatment allocation, and a Trial Steering Committee will provide oversight of the trial.

The primary trial results will be submitted for publication to an international, peer-reviewed journal, regardless of the nature of the results. Authorship will be determined by the chief investigators in accordance with the ALABAMA Publication Policy developed with the Trial Management Group in accordance with the ICMJE guidelines and other contributors will be acknowledged. Patient and public dissemination is also planned. The data that support the findings of this study will be available on reasonable request.
DISCUSSION

The importance of AMR and the need to reduce its impact is well recognised. Penicillins are the most commonly prescribed antibiotics and remain first-line therapy for many common infections. However, allergy to penicillin is commonly reported by patients and the presence of a PEN allergy record in a patient’s health record leads to the avoidance of recommended first-line penicillin antibiotics. Non-penicillin antibiotics can be less effective, have more side effects and have a greater propensity to drive AMR.

Evidence shows that approximately 5% of patients who have a PEN allergy record are found to have genuine allergy after non-specialist allergy assessment. This trial aims to address the large discrepancy between reported and true allergy rates and will determine if introducing ‘pre-emptive’ testing for patients who are more likely to receive antibiotics in the future, could impact on antibiotic prescribing, yield patient benefits, limit AMR/healthcare associated infection and deliver NHS cost savings.

The novel design of the PAAP allows direct oral challenge testing of patient participants deemed to have low risk of a genuine allergic reaction and is intended to make the PAT more efficient. If PAAP is found to be acceptable to patients, this streamlined approach to PAT would enable more patients to be tested within current resources. Additionally, PAAP need not be confined to take place in an immunology clinic and could be undertaken by appropriately trained staff, such as pharmacists, in all units with facilities to deal with any potential severe allergic reaction.

The PAAP is supported by a behavioural package, providing support materials to clinicians and participants to encourage referral to and attendance at PAAP and prescription and use of penicillin following delabelling, where appropriate. These materials were developed with input from stakeholders including PPIE-AF patient public involvement contributors to ensure they address clinician and participants’ needs.

Other strengths of the ALABAMA study include the nested pilot study which ensured the safety of PAAP before transition to the main trial and the multicentre design which allows recruitment of patients from a number of primary care regions across the UK, thus reinforcing the external validity of the trial. In addition, the mixed-methods process evaluation will allow us to understand how the intervention package was used by clinicians and participants, help to interpret the trial findings and provide an insight into optimal implementation. As a result, positive findings from the ALABAMA trial will be readily implementable in the NHS.

This trial has developed unique trial processes utilising SystmOne for data collection which will be discussed elsewhere, however this novel technology can potentially be used to improve trial processes for future primary care research.

The ALABAMA trial is being conducted amidst the COVID-19 pandemic and therefore will provide an insight into the effect of the pandemic on trial processes, in particular on participant recruitment and on how safety procedures for participants and trial staff are implemented.

This trial is the largest randomised trial aiming to pre-emptively address incorrect penicillin allergy records and has potential to significantly impact care by improving patient health outcomes, improving antibiotic prescribing, reducing AMR and overall reducing NHS costs.

A potential limitation is that the trial recruitment period includes the COVID-19 pandemic, which may have influenced antibiotic prescribing rates.

The process evaluation will review delabelling procedures with GPs. As the trial is open label and delabelling of participants in the intervention arm may influence clinician behaviour across all participants, it will be prudent to monitor this impact. Baseline rates of penicillin prescribing practice of those with a PEN allergy are not formally captured in the trial participating sites, although we do know the national average (4%). This will warrant further local audits within SystmOne and/or closer working with NHS-England that are now monitoring this behaviour in some geographic areas of relevance to the trial.

Trial status

Enrolment started at the first GP site as part of the feasibility study in October 2019. The current protocol is version 10.0 03-OCT-2022.

Author affiliations

1Nuffield Department of Primary Care Health Sciences, Clinical Trials Unit, University of Oxford, Oxford, UK
2Dental Translational and Clinical Research Unit, School of Dentistry, University of Leeds, Leeds, UK
3Leeds Teaching Hospitals NHS Trust, Leeds, UK
4Leeds Institute of Medical Research, School of Medicine, University of Leeds, Leeds, UK
5School of Healthcare, University of Leeds, Leeds, UK
6NHS England, Leeds, UK
7Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
8Clinical Immunology and Allergy, University of Leeds Leeds Institute of Medical Research at St James’s, Leeds, UK
9Leeds Institute of Health Sciences, University of Leeds, Leeds, UK

Twitter Christopher C Butler @ChrisColButler

Acknowledgements We acknowledge and thank the hard work and dedication of all the NIHR Clinical Research Networks recruitment teams, general practices and secondary care intervention sites. The authors would like to acknowledge the contribution of the Trial Steering Committee members and the Data Monitoring Committee members. The ALABAMA research team would like to thank the following PPIE-AF members for their valuable contribution—Rosie Woollard, Jenny Boards, Mandy East and Lynne Regent at Anaphylaxis UK, Maureen Jenkins and Amanda Warner at Allergy UK.

Contributors Conceptualisation, JS, SP, CCB, SS, EB, PH and ST-C; methodology, JS, SP, JB, SA, KFA, CP, MD, JC, EB, PH, RS, RM-M and KC; formal analysis, UG, RMW, L-MY, ST-C, MW and MS; investigation, SS, SA, RS, MW and MS; resources, JS, SP, CCB, SS, EB and ST-C; data curation, UG, L-MY, ST-C, MW, MS and RM-M; writing—original draft preparation, KFA, CP and MD; writing—review and editing, all; supervision, EB, JC, JS and SP; project administration, CP, KFA, MD and KC; funding acquisition, JS, CCB, PH, ST-C, BS and SP. All authors have read and agreed to the published version of the manuscript.

Funding This work was supported by National Institute for Health and Care Research (NIHR) Programme Grant for Applied Research (PGfAR)—grant number RP-PG-1214-20007.

Disclaimer The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Competing interests None declared.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Kelsey Fiona Armitage http://orcid.org/0000-0001-5438-5290
Emily Bongard http://orcid.org/0000-0001-5957-6280
Christopher C Butler http://orcid.org/0000-0002-0102-3453
Razan Saman http://orcid.org/0000-0002-0733-9244
Marta Santillo http://orcid.org/0000-0001-6345-7617
Sarah Tonkin-Crine http://orcid.org/0000-0003-4470-1151
Marta Wanat http://orcid.org/0000-0002-0163-1547
Robert M West http://orcid.org/0000-0001-7305-3654

REFERENCES
9 Reddy V, Barnas NS, Whitener C, et al. Drug resistant infections with Mecillin-resistant Staphylococcus aureus, Clostridium difficile, and vancomycin resistant Enterococcus are associated with a higher prevalence of penicillin allergy. Journal of Allergy and Clinical Immunology 2013;131:AB170.
12 WHO. WHO AWaRe classification database of antibiotics for evaluation and monitoring of use. 2019.
ALABAMA Trial Verbal CONSENT FORM

Trial Title: Allergy Antibiotics and Microbial resistance (ALABAMA): Penicillin allergy status and its effect on antibiotic prescribing, patient outcomes, and antimicrobial resistance.

Participant ID: ___________ GP Practice Name: ___________

REC No: 19/LO/0176 Patient’s name, Date of birth and GP surgery name confirmed? Tick __ __

Investigators: Dr Jonathan Sandoe, Prof Sue Pavitt

1. Do you confirm that you have read and understood the ALABAMA Information Sheet version number _______ dated: __ __ / __ __ / __ __ __ __ and you have had the opportunity to consider the information, ask questions, and have had these answered satisfactorily.

2. Do you understand your participation is voluntary and that you are free to withdraw at any time, without giving any reason, and without your medical care or legal rights being affected and that you understand that data collected up to your time of withdrawal may still be used?

3. Do you understand that you will be randomised to either usual clinical care, or penicillin-allergy assessment pathway (PAAP)? You will be told which trial group you are in.

4. Do you understand if you are in the PAAP group you will attend an additional appointment at the immunology clinic, Do you understand this appointment will involve skin testing (ST) and/or taking syrup solution containing penicillin called oral challenge test (OCT).

5. Do you understand that if your PAAP result shows no penicillin allergy, your medical records will be updated and for future infections that require antibiotic treatment you may be prescribed a penicillin based antibiotic.

6. Do you understand that you will be required to provide information to the research team through electronic, paper and telephone questionnaires? Do you consent to the ALABAMA research team to access, transfer and store this paper and electronic data.

7. Do you consent to being contacted by the research team for the purposes of trial follow up and you understand that this will require you to provide the research team with your name and contact details. Do you agree to the transfer and storage of this data for use in the ALABAMA trial?

8. Do you understand that your medical records, including information about general medical history, penicillin allergy history, visits to hospital, other NHS resource use and antimicrobial prescriptions will be reviewed and data collected by the ALABAMA research team for ten years after trial has ended. Do you permit these individuals to have access to your history, visits to hospital, other NHS resource use and antimicrobial prescriptions will be reviewed and data collected by the trial team to the data collected during the ALABAMA trial?

9. Do you understand that your name, date of birth and NHS Number will be shared with NHS Digital to enable them to supply the trial team with additional data about you for ten years after trial has ended? This may include Hospital Episode Statistics data and Mortality data. The data supplied by NHS Digital is linked by the trial team to the data collected during your participation in the ALABAMA trial. You are free to withdraw your consent for data linkage with NHS Digital at any time and it will not affect your ongoing care.

10. Do you give permission for your data collected for the trial and up to 10 years after the trial has ended, to be looked at by authorised individuals from the University of Leeds, University of Oxford, authorised collaborators within the ALABAMA Trial and regulatory authorities for research purposes? Do you understand that all information collected will be used for medical research only and that you will not be identified in any way in the analysis and reporting of the results?

11. Do you consent to your GP being informed of your participation within the trial and the results of the PAAP testing (if applicable)?

12. Do you give permission for secondary use of your data for further research studies after the end of the trial?

13. Do you agree to take part in the ALABAMA trial?

14. OPTIONAL: Do you agree to potentially be contacted to take part in a telephone interview to discuss your experience of taking part in the ALABAMA trial?

Name of Person Taking Consent (Print) ___________________________ Date ______________ Signature ___________________________

Name of Participant (Print) ___________________________ Date ______________

No signature obtained from the participant as verbal consent taken by telephone.

IRAS Number: 252976 ALABAMA Verbal Consent Form V3.0 05Nov2021

When completed, store top copy in Site File & send bottom copy in post to participant & scan a copy in Medical Notes.

ALABAMA Trial ADULT CONSENT FORM

Trial Title: Allergy AntiBiotics And Microbial resistAnce (ALABAMA): Penicillin allergy status and its effect on antibiotic prescribing, patient outcomes, and antimicrobial resistance.

Participant ID: ____________________ REC Number: 19/LO/0176

Chief Investigators: Dr Jonathan Sandoe, Prof Sue Pavitt

1. I confirm I have read and understood the ALABAMA Participant Information Sheet version number __________ dated: __ __ / __ __ __ / __ __ __ __. I have had the opportunity to consider the information, ask questions, and have had these answered satisfactorily.

2. I understand my participation is voluntary and that I am free to withdraw at any time, without giving any reason, and without my medical care or legal rights being affected. I understand that data collected up to my time of withdrawal may still be used.

3. I understand that I will be randomised to either usual clinical care, or penicillin-allergy assessment pathway (PAAP). I will be told which trial group I am in.

4. If I am in the PAAP group I will attend an additional appointment at the immunology clinic, I understand this appointment will involve skin testing (ST) and /or taking syrup solution containing penicillin called oral challenge test (OCT).

5. I understand that if my PAAP result shows no penicillin allergy, my medical records will be updated and for future infections that require antibiotic treatment I may be prescribed a penicillin based antibiotic by my GP.

6. I understand that I will be required to provide information to the research team through electronic, paper and telephone questionnaires. I consent to the ALABAMA research team to access, transfer and store this paper and electronic data.

7. I consent to being contacted by the research team for the purposes of trial follow up and I understand that this will require me to provide the research team with my name and contact details. I agree to the transfer and storage of this data for use in the ALABAMA trial.

8. I understand that my medical records, including information about general medical history, penicillin allergy history, visits to hospital, other NHS resource use and antimicrobial prescriptions will be reviewed and data collected by the ALABAMA research team for ten years after trial has ended. I permit these individuals to have access to my electronic health records and paper health records and any records held by NHS Digital.

9. I understand that my name, date of birth and NHS Number will be shared with NHS Digital to enable them to supply the trial team with additional data about me for ten years after trial has ended. This may include Hospital Episode Statistics data and Mortality data. The data supplied by NHS Digital is linked by the trial team to the data collected during my participation in the ALABAMA trial. I am free to withdraw my consent for data linkage with NHS Digital at any time and it will not affect my ongoing care.

10. I give permission for my data collected for the trial and up to 10 years after the trial has ended, to be looked at by authorised individuals from the University of Leeds, University of Oxford, authorised collaborators within the ALABAMA Trial and regulatory authorities for research purposes. I understand that all information collected will be used for medical research only and that I will not be identified in any way in the analysis and reporting of the results.

11. I consent to my GP being informed of my participation within the trial and the results of the PAAP testing (if applicable).

12. I give permission for secondary use of my data for further research studies after the end of the trial.

13. I agree to take part in the ALABAMA trial.

14. OPTIONAL: I agree to potentially be contacted to take part in a telephone interview to discuss my experience of taking part in the ALABAMA trial.

Name of Person Taking Consent (Print) ____________________ Date ______________ Signature ____________________

Name of Participant (Print) __________________________________________ Date ______________ Signature ____________________

IRAS Number: 252976

ALABAMA Consent Form V3.0 15 Jan 2021

When completed, store top copy in Site File & scan into Medical Notes; give bottom copy to participant.

## APPENDIX A: ALABAMA Infections for which an antibiotic prescription would be considered a primary event, and subsequently assessed for primary trial outcome.

<table>
<thead>
<tr>
<th>Infection Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute sore throat, pharyngitis, tonsillitis</td>
</tr>
<tr>
<td>Oral infection</td>
</tr>
<tr>
<td>Parotitis, salivary gland infection</td>
</tr>
<tr>
<td>Community acquired pneumonia</td>
</tr>
<tr>
<td>Chest infections i.e. 'acute bronchitis’ or ‘lower respiratory infection’ or unspecified</td>
</tr>
<tr>
<td>Acute otitis media</td>
</tr>
<tr>
<td>Acute bacterial rhinosinusitis</td>
</tr>
<tr>
<td>Infective COPD exacerbation: amoxicillin or doxycycline first line unless patient at higher risk of treatment failure then co-amoxiclav; empirical treatment or guided by most recent sputum culture and susceptibilities</td>
</tr>
<tr>
<td>acute exacerbation of bronchiectasis</td>
</tr>
<tr>
<td>Skin and soft tissue infection (cellulitis, surgical wound infection, infected ulcer/pressure sore, erysipelas, boil, faruncule, impetigo etc)</td>
</tr>
<tr>
<td>Diverticulitis</td>
</tr>
<tr>
<td>Dental Abscesses</td>
</tr>
</tbody>
</table>
3. Appendix 3: ALABAMA SOP, Skin Prick and Intradermal Allergy Test

<table>
<thead>
<tr>
<th>Standard Operating Procedure</th>
<th>Skin Prick and Intradermal Allergy Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Version No.</td>
<td>V4.0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Contributor</th>
<th>Name</th>
<th>Date</th>
<th>Signed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Written by:</td>
<td>Robert White Research Nurse</td>
<td>01.10.20</td>
<td>[Signature]</td>
</tr>
<tr>
<td>Updated by:</td>
<td>Shadia Ahmed Research Fellow</td>
<td>10.05.22</td>
<td>[Signature]</td>
</tr>
<tr>
<td>Approved by:</td>
<td>Dr. Sinisa Savic Consultant Immunologist</td>
<td>10.05.22</td>
<td>[Signature]</td>
</tr>
</tbody>
</table>
Standard Operating Procedure

Skin Prick and Intradermal Testing

The following standard operating procedure outlines how to perform a skin prick test and is applicable to all health care professionals undertaking this role.

Skin prick (SPT) and intradermal (IDT) testing (SPT) are methods used to determine the presence of specific Immunoglobulin E (IgE) mediated reactions. SPT and IDT should be performed by an appropriately trained and competent healthcare worker who is also trained in recognition and treatment of anaphylaxis.

4. EXCLUSIONS:

SPT and IDT reactions are inhibited by antihistamines and may be inhibited by tricyclic antidepressants, tetracyclic antidepressants, topical corticosteroids and UV light treatment. Where possible inhibitory medication should be stopped at least 72 hours prior to testing.

Note - Patient’s who are taking antihistaminergic medication, might still be suitable to continue with oral challenge
5. **CAUTIONS:**

Caution should be taken when considering SPT/IDT in pregnancy, for patients with unstable asthma or those taking beta blockers and/or ACE inhibitors.

6. **EQUIPMENT:**

   **SPT and IDT**
   - PPE - Follow current LTHT guidelines (available on LTHT Intranet)
   - Skin Marker/Pen
   - Sharps bin
   - Tissue Paper
   - Micropore tape
   - Skin test measure
   - Timer (clock/watch)
   - Emergency equipment available to treat anaphylaxis.
   - ADULT Skin Prick & Intradermal Testing - Medications *(Appendix 1)*
**SPT**
- Positive control - Histamine 10mg/mL in 50% glycerol and 50% buffered 0.9% sodium chloride
- Negative control - 50% glycerol and 50% buffered 0.9% sodium chloride
- Test allergen solution (Amoxicillin 20mg/ml, +/- index penicillin if different to these). *
- Individual sterile skin prick testing lancets

**IDT**
- Negative control-normal saline (NB positive control is not used in IDT)
- Test allergen solution (Amoxicillin 20mg/ml, +/- index penicillin if different to these). *
- Needle 30G
- Syringe 1mL
- Alcohol wipe

*Refer to Appendix 2 for instructions for how to make testing dilutions.*

**7. PREPARATION:**

The procedure should be undertaken in accordance with LTHT Covid-19 Coronavirus Guidelines and local infection control policy.

Perform positive ID Check, discuss procedure with patient and gain verbal consent. Check current medications with patient & SystmOne (see Exclusions & Cautions). Select appropriate test site free from eczema / dermatitis, the preferred site is the forearm.

**8. PROCEDURE:**

**STP and IDT**

1. Ensure the patient is in a comfortable sitting position or, if needle phobic, lying down. Rest arm on a level surface, using a pillow if necessary.

2. Perform hand hygiene and don any outstanding PPE.

3. Remove appropriate garments to expose the testing site (typically skin of the forearm).
4. Assess the injection site for signs of inflammation, oedema, infection, and skin lesions.

9. SPT

5. Ensure test site is free from body lotion and moisturisers. The Test site should be hygienically clean but does not need to be cleaned with alcohol or antiseptic. Do not rub the area as this will create erythema.

6. Beginning with the positive control and ending with the test allergens (Amoxicillin, +/- index penicillin if different to these) use micropore tape to mark the test sites approximately 2.5cm apart, using first letter of allergen/control being tested (e.g. +, -, A). Place marked micropore tape on midline of forearm. Avoid the skin creases (elbow and wrist).

7. Place one drop of each selected allergen solution on the skin next to relevant marked site.

8. Using gentle pressure, push the lancet through allergen solution and into the surface layer of the skin.

9. Discard lancet into sharps bin.

10. Repeat the procedure for each allergen and the controls using a new lancet each time.

11. Remove surplus allergen by blotting test sites with tissue paper ensuring that no cross contamination between test sites occurs.

10. IDT (if SPT is negative and if indicated please proceed to IDT)

1. Attach 30G needle to 1ml syringe containing test solution / article.

2. Apply gloves and clean the injection site with a swab saturated with isopropyl alcohol 70% and apply gloves.

3. Remove the needle sheath and hold syringe with the dominant hand with the bevel of needle pointing up.
4. Beginning with the negative control use the non-dominant hand to stretch skin over the site with forefinger and thumb.

5. With the syringe almost against the patient's skin, insert the needle into the skin at an angle of 10–15° and advance through the epidermis so the needle tip can be seen through the skin.

6. Inject medication slowly. It is not necessary to aspirate as the dermis is relatively avascular.

7. While injecting medication, a bleb (resembling a mosquito bite) will form.

8. When a 3-5mm bleb is observed withdraw the needle rapidly. Do not massage the site.

9. Dispose of contaminated sharps into sharps bin.

10. Using skin marker draw around the formed bleb.

11. Repeat the procedure for each allergen and the controls.

11. SPT and IDT

1. Advise patients not to scratch the test sites whilst waiting for the results to develop.

2. Ask patients to report any systemic adverse reaction (e.g. dyspnoea, dizziness).

3. Results should be read 15-20 minutes after the test. Measure the wheal diameter in mm. For asymmetric wheals measure the longest extent of the wheal in mm and the extent 90° to the first measurement (e.g. 3x3mm).

4. Record the outcome of the test in the source document.

5. Topical 1% hydrocortisone, oral anti-histamines or a cold compress may be given to relieve severe itch in line with a prescription.
12. INTERPRETATION:

Test sites are examined for wheal or flare after 15 - 20 minutes has elapsed. For SPT any site with a wheal diameter of ≥ 3mm compared to negative control is considered a positive result. For IDT any site with a hive and associated redness and swelling outside the marked area ≥ 3mm compared to the initial bleb or negative control is considered a positive result.

13. COMPLICATIONS:

Mild pruritus localised to positive test sites is the most common complication and usually resolves with no intervention.

Although SPT is a common procedure and regarded as safe, the possibility of a systemic reaction remains a possibility.

14. AFTERCARE:

If no adverse reaction has occurred, the patient is free to leave the clinic.

In case of late phase response, the patient must be instructed to call 111 or visit their local Emergency Department should they develop symptoms of dyspnoea, wheezing, dizziness or severe pruritus.
### 15. Appendix 3.1: ADULT: Skin Prick & Intradermal Testing - Medications

Have any antihistamines, corticosteroids, anti-depressants, antipsychotics or ACE inhibitors been taken recently?

<table>
<thead>
<tr>
<th>Drug/Allergen</th>
<th>Dilution</th>
<th>SPT Drug/Allergen Required</th>
<th>wheal Size (mm)</th>
<th>IDT Drug/Allergen Required</th>
<th>wheal Size (mm) at time zero</th>
<th>wheal Size (mm) at 15mins</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive Control - Histamine</td>
<td>10mg/mL</td>
<td>Prescriber</td>
<td></td>
<td>Prescriber</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative Control - Sodium Chloride</td>
<td>0.9%</td>
<td>Prescriber</td>
<td></td>
<td>Prescriber</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMOXICILLIN</td>
<td>20mg/mL</td>
<td>Prescriber</td>
<td></td>
<td>Prescriber</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BENZYLPERCILLIN</td>
<td>6mg/mL</td>
<td>Prescriber</td>
<td></td>
<td>Prescriber</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CO-AMOXICLAV</td>
<td>20mg/mL</td>
<td>Prescriber</td>
<td></td>
<td>Prescriber</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FLUCLOXACILLIN</td>
<td>20mg/mL</td>
<td>Prescriber</td>
<td></td>
<td>Prescriber</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Prescribed by: [Signature] 
SPT administered by: [Signature] 
IDT administered by: [Signature] 

Compiled by: [Signature] Date: 19 Aug 2019 Approved by: [Signature] Date: 02 Sep 2019
### Amoxicillin

<table>
<thead>
<tr>
<th>Strength /formulation</th>
<th>Concentration</th>
<th>Dilution instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin prick test</td>
<td>20mg/ml</td>
<td>Reconstitute the 250mg vial with 5mls water for injection to give approx. 50mg/ml solution. Withdraw 0.4mls and dilute with 0.6mls sodium chloride 0.9% to give a 20mg/ml solution.</td>
</tr>
<tr>
<td>Intradermal test</td>
<td>20mg/ml</td>
<td>As above</td>
</tr>
</tbody>
</table>

**Comments**

If the specified formulation is not available then the dilution instructions will need to be amended accordingly.

**References**


### Amoxicillin 500mg

<table>
<thead>
<tr>
<th>Undiluted strength /formulation</th>
<th>500mg powder for injection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin prick test</td>
<td></td>
</tr>
<tr>
<td>Concentration</td>
<td>20mg/ml</td>
</tr>
<tr>
<td>Dilution instructions</td>
<td>1. Reconstitute the 500mg vial with 10mls water for injection to give a 50mg/ml solution. 2. Withdraw 4mls (200mg) and dilute with 6mls sodium chloride 0.9% to give a 20mg/ml solution.</td>
</tr>
<tr>
<td>Intradermal test</td>
<td></td>
</tr>
<tr>
<td>Concentration</td>
<td>20mg/ml</td>
</tr>
<tr>
<td>Dilution instructions</td>
<td>As above</td>
</tr>
</tbody>
</table>

**Comments**

If the specified strength and formulation is not available then the dilution instructions will need to be amended accordingly.

**References**

<table>
<thead>
<tr>
<th>Benzyl penicillin</th>
<th><strong>Strength /formulation</strong></th>
<th>600mg powder for injection</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Skin prick test</strong></td>
<td>Concentration</td>
<td>6mg/ml</td>
</tr>
<tr>
<td>Dilution instructions</td>
<td>Reconstitute the 600mg vial with 10mls water for injection to give 60mg/ml. Withdraw 0.1mls (6mg) and dilute this with 0.9mls sodium chloride 0.9% to give a 6mg/ml solution</td>
<td></td>
</tr>
<tr>
<td><strong>Intradermal test</strong></td>
<td>Concentration</td>
<td>6mg/ml</td>
</tr>
<tr>
<td>Dilution instructions</td>
<td>As above</td>
<td></td>
</tr>
</tbody>
</table>

**Comments**
- If the specified formulation is not available then the dilution instructions will need to be amended accordingly.
- Once reconstituted products must be used immediately.

**References**
## Appendix 3.2: Dilution instructions

### Co-amoxiclav

<table>
<thead>
<tr>
<th>Strength /formulation</th>
<th>1.2g, powder for solution for injection /infusion</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Skin prick test</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Concentration</strong></td>
<td>20mg/ml</td>
</tr>
<tr>
<td><strong>Dilution instructions</strong></td>
<td>Reconstitute with 20mls water for injections to give 50mg /ml</td>
</tr>
<tr>
<td></td>
<td>Withdraw 0.4mls (20mg) and dilute up to 1ml of sodium chloride 0.9% (to give 20mgs/ml)</td>
</tr>
<tr>
<td><strong>Intradermal test</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Concentration</strong></td>
<td>20mg/ml</td>
</tr>
<tr>
<td><strong>Dilution instructions</strong></td>
<td>As above</td>
</tr>
</tbody>
</table>

**Comments**

Note the concentration above (20mg/ml) only takes into account the amoxicillin component (not the clavulanic acid component)

If the specified formulation is not available then the dilution instructions will need to be amended accordingly.

Once reconstituted products must be used immediately.

**References**


### Flucloxacillin

<table>
<thead>
<tr>
<th>Strength /formulation</th>
<th>250mg, powder for solution for injection /infusion</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Skin prick test</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Concentration</strong></td>
<td>20mg/ml</td>
</tr>
<tr>
<td><strong>Dilution instructions</strong></td>
<td>Reconstitute with 5mls of water for injection to give 50mgs/ml. Withdraw 0.4mls (20mg). Then dilute up to 1mls with sodium chloride 0.9% to give 20mgs/ml</td>
</tr>
<tr>
<td><strong>Intradermal test</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Concentration</strong></td>
<td>20mg/ml</td>
</tr>
<tr>
<td><strong>Dilution instructions</strong></td>
<td>As above.</td>
</tr>
</tbody>
</table>

**Comments**

If the specified formulation is not available then the dilution instructions will need to be amended accordingly.

Once reconstituted products must be used immediately.

**References**

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Concentration</th>
<th>Dilution Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Skin prick test</strong></td>
<td>20mg/ml</td>
<td>1. Reconstitute the 500mg vial with 10mls water for injection to give 50mg/ml</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2. Withdraw 0.4mls (20mg) and dilute to 1ml with sodium chloride 0.9% (= 20mgs/ml)</td>
</tr>
<tr>
<td><strong>Intradermal test</strong></td>
<td>20mg/ml</td>
<td>As above</td>
</tr>
</tbody>
</table>

**Comments**: If the specified strength and formulation is not available then the dilution instructions will need to be amended accordingly.

17. Appendix 3.3: Anaphylactic Reaction flowchart

**ANAPHYLACTIC REACTION?**

- Airway, Breathing, Circulation, Disability, Exposure

**Diagnosis - Look for:**
- Acute onset of illness
- Life-threatening Airway and/or Breathing and/or Circulation problems
- And usually skin changes

**Call for help > Lie patient flat > Raise patient legs**

**Adrenaline**

**When skills and equipment available:**
- Establish airway
- High flow oxygen
- IV fluid challenge
- Chlorphenamine
- Hydrocortisone
- Monitor: Pulse, Oxygen, ECG, Blood pressure

1. **Life-threatening problems**
   - Airway: swelling, hoarseness, stridor
   - Breathing: rapid breathing, wheeze, agitation, cyanosis, 
     SaO2 < 82%, confusion
   - Circulation: pale, clammy, low blood pressure, faintness, drowsy/concern

2. **Adrenaline** (give IM unless experienced with IV adrenaline)
   - IM dose of 0.01 mg adrenaline (repeat after 5 mins if no improvement)
   - Adult > 12 years: 500 micrograms IM (0.5 mL)
   - Child 0 – 12 years: 300 micrograms IM (0.3 mL)
   - Child < 6 years: 150 micrograms IM (0.1 mL)

3. **IV fluid challenge**
   - Adult: 500 to 1000 mL
   - Child: crystallised 20mL/Kg
   - Stop IV soloid if this might be cause of anaphylaxis

4. **Chlorphenamine**
   - Adult or child > 12 years: 10 mg
   - Child 0 – 12 years: 5 mg
   - Child 0 months - 1 year: 2.5 mg
   - Child < 6 months: 200 micrograms/Kg

5. **Hydrocortisone**
   - Adult or child > 12 years: 200 mg
   - Child 0 – 12 years: 100 mg
   - Child 0 months - 1 year: 50 mg
   - Child < 6 months: 20 mg

The Leeds Teaching Hospitals NHS Trust

BIBLIOGRAPHY:


ALABAMA SOP- Oral Challenge Test - Penicillins Version 5.0 06/05/2022
### Appendix 4: ALABAMA SOP, Oral Challenge Test – Penicillin

<table>
<thead>
<tr>
<th>Standard Operating Procedure</th>
<th>Oral Challenge Test - Penicillins</th>
</tr>
</thead>
<tbody>
<tr>
<td>Version No.</td>
<td>V5.0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Contributor</th>
<th>Name</th>
<th>Date</th>
<th>Signed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Written by</td>
<td>Robert White</td>
<td>01.10.20</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Research Nurse</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Updated by</td>
<td>Shadia Ahmed</td>
<td>06.05.22</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Research Fellow</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Approved by</td>
<td>Dr. Sinisa Savic</td>
<td>06.05.22</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Consultant Immunologist</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Filename:</th>
<th>ALABAMA SOP - Oral Challenge Test - Penicillins.docx</th>
</tr>
</thead>
<tbody>
<tr>
<td>Location of copies:</td>
<td>1. Clinical Immunology &amp; Allergy, Ground Floor, Beckett Wing, SJUH</td>
</tr>
<tr>
<td></td>
<td>2. ALABAMA Investigator Site File, Infection Research Office, Level 8 Gledhow Wing, SJUH.</td>
</tr>
<tr>
<td></td>
<td>3. ALABAMA Study Folder, Infection Research Network Drive</td>
</tr>
<tr>
<td></td>
<td>4. ALABAMA ‘PAAP SOPs’ folder, shared ‘N’ drive, UoL</td>
</tr>
</tbody>
</table>

ALABAMA SOP- Oral Challenge Test - Penicillins Version 5.0 06/05/2022
Standard Operating Procedure

Oral Challenge Test to Penicillins

The following standard operating procedure outlines how to perform an Oral Challenge Test to penicillins and is applicable to all health care professionals undertaking this role.

In the diagnosis of drug allergy an oral challenge test is considered the ‘gold standard’ due to the unreliability of other testing methods. An oral challenge test (OCT) involves administering the test drug in increasing doses until a reaction occurs or the usual prescribed dose level is reached. Alternatively patients can be given a single dose, where the risk of possible reaction is judged to be extremely low.

Oral Challenge Testing to penicillins should only be performed by an appropriately trained and competent healthcare worker who is also trained in recognition and treatment of anaphylaxis.

EXCLUSIONS

- Antihistamines within 72 hours of OCT
- Beta-blocker within 24 hours of OCT
- Steroids within 10 days of OCT
- History of Anaphylaxis
- History of Stevens-Johnson syndrome, toxic epidermal necrolysis, serum sickness, acute interstitial nephritis, hemolytic anemia, and drug rash with eosinophilia and systemic symptoms (DRESS)
- Severe/brittle asthma or unstable coronary artery disease
- Pregnancy
- Currently taking antibiotics for active infection*

*Long term prophylactic antibiotics may be continued in certain scenarios after discussion with the medical team.
EQUIPMENT:

- 100mL Amoxicillin 250mg/5mL (or different when index Penicillin is known)
- 50mL Sodium Chloride 0.9%
- Oral Challenge Test Prescription Chart (Appendix 4)
- Observational monitoring chart (Appendix 3)
- PPE - Follow current LTHT guidelines (available on LTHT Intranet)
- Syringes 1mL, 2.5mL & 10mL
- Sharps bin
- Timer (clock/watch)
- Emergency equipment available to treat anaphylaxis
- 18G Needles
- Needle free device (Bionector connector)
- IV cannulation pack: Steret, gauze, 20G cannula, tegaderm (n.b cannulation prior OCT is not needed routinely for patients deemed to have low risk of reaction)

PREPARATION:

The procedure should be undertaken in accordance with LTHT Covid-19 Coronavirus Guidelines and local infection control policy.

Perform positive ID check, ensure prescription is valid and rescue medications are prescribed (Refer to prescription chart). Discuss the procedure with the patient; written consent for the procedure must be obtained. The procedure must only be undertaken if the patient is well. Check current health status/ current medications with patient and SystmOne. The test must be cancelled if the patient has intercurrent infection, uncontrolled asthma, cardiac problems, or has taken medications likely to interfere with the challenge test (see Exclusions & Cautions).
PROCEDURE:

1. Perform hand hygiene and don any outstanding PPE.

2. Perform a set of baseline observations (BP, Pulse, Sp02) and document.

3. Ensure patient is in a comfortable position.

4. Some patients will require cannulation as confirmed by the medic on duty.

5. The following standard dosing regimen should be used routinely. For patients who are deemed low risk use the dosing schedule outlined in Appendix 5.

6. Administer 10% of the standard dose of the test drug (e.g. usual dose of amoxicillin or penicillin V = 500mg - start with 50mg) and document.

7. Ask the patient to report any adverse reaction (Appendix 1), monitor for 15-20 minutes and perform a set of observations (BP, Pulse, Sp02) and document.

8. If no reaction or significant change in observations then administer further 25% of the standard dose of the test drug (e.g. 125mg of amoxicillin or penicillin V when the standard dose is 500mg) and document.

9. Ask the patient to report any adverse reaction (Appendix 1), monitor for 15-20 minutes and perform a set of observations (BP, Pulse, Sp02) and document.

10. If no reaction or significant change in observations then administer the final standard dose (500mg of amoxicillin or penicillin V) and document.

11. Ask the patient to report any adverse reaction (Appendix 1), monitor for 30 minutes and perform a set of observations (BP, Pulse, Sp02) and document.

12. Document test result and reactions in Appendix 3 and explain the results of the test to the patient.

13. Supply the patient with the remaining 100ml of the appropriate antibiotic (amoxicillin/penicillin V or other) used in the challenge test, as prescribed for home dosing.
14. Beginning with the first dose on the evening of the oral challenge test, instruct the patient to take the standard dose of the appropriate antibiotic (500mg of amoxicillin or penicillin V) three times daily until the course is completed.

15. Refer to AFTERCARE and provide the patient with the post allergy testing information sheet.

16. Once the D4-6 follow-up call is completed, scan and email appendix 3 (with all other PAAP testing documentation) to the Allergy/Immunology secretaries for upload to patient electronic health records (e.g. PPM+).

INTERPRETATION:

Any positive reaction (Appendix 1) should be documented and the test stopped.

Reactions should be treated appropriately - See Appendix 2.

COMPLICATIONS:

Although OCT is a common procedure and regarded as safe, the possibility of a systemic reaction remains a possibility.

AFTERCARE:

If no adverse reaction has occurred, the patient is free to leave the clinic.

In case of late phase response, the patient must be instructed to call 111 or visit their local Emergency Department should they develop symptoms of dyspnoea, wheezing, dizziness or severe pruritus.
19. Appendix 4.1: Signs & Symptoms of allergic reactions in various target organs.

**Skin:**
- Urticaria/Angioedema
- Flushing
- Erythematous pruritic rash
- Atopic dermatitis

**Gastro-intestinal tract:**
- Pruritis and/or swelling of the lips, tongue or oral mucosa
- Nausea
- Abdominal cramping or colic
- Vomiting or reflux
- Diarrhoea

**Respiratory tract:**
- Nasal congestion
- Rhinorrhea
- Pruritis/sneezing
- Laryngeal oedema, staccato cough and/or dysphonia
- Wheezing/ repetitive cough

**Cardiovascular:**
- Hypotension/shock
- Dizziness
20. Appendix 4.2: Treatment of positive reactions during oral challenge testing.

**Mild reactions:**

- Ensure patient is comfortable
- Administer 10mg Cetirizine orally and monitor patient.

**Severe reactions:**

- Contact medical team
- Assist patient into a comfortable position; recovery position for hypotension/faintness, upright for dyspnoea
- Administer oxygen and nebulised salbutamol if required
- Prepare anaphylactic pack to administer 0.5mL adrenaline 1:1000 Intra-muscular
- Call Resuscitation Team if necessary
- Commence CPR if required.
21. **Appendix 4.3: Observational monitoring chart.**

<table>
<thead>
<tr>
<th>Date:</th>
<th>Drug &amp; Concentration Tested:</th>
<th>Patient Name:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NHS No:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Dose Administered</th>
<th>Blood Pressure</th>
<th>Pulse</th>
<th>Sp02</th>
<th>Symptoms/Reactions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Testing performed by: ....................  Signature: ....................  Date: ....................

Document the result of the test clearly in the box below (After the D4-6 follow-up call):

<table>
<thead>
<tr>
<th>RESULT OF TEST:</th>
<th>NEGATIVE</th>
<th>POSITIVE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ADVICE FOR PATIENT

<table>
<thead>
<tr>
<th>SAFE TO TAKE DRUG AGAIN IN FUTURE</th>
<th>MUST AVOID DRUG IN FUTURE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Test result completed by: ....................  Signature: ....................  Date: ....................

Page 85
### 22. Appendix 4.4: Oral Challenge Test Prescription Chart (LTHT specific – other sites feel free to use own/localise this version)

<table>
<thead>
<tr>
<th>First Name</th>
<th>Surname: (Block Letters)</th>
<th>Allergies and Adverse Drug Reactions - List the medicines or substances &amp; the nature of the reaction (write NKDA if none)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital No</td>
<td>NHS No:</td>
<td>DOB:</td>
</tr>
<tr>
<td>Consultant:</td>
<td>Ward:</td>
<td>Hospital:</td>
</tr>
<tr>
<td>(Use addressograph if available)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For emergency use in case of allergic reaction:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Route</th>
<th>Prescribers Signature</th>
<th>PRINT name &amp; Contact no.</th>
<th>Date</th>
<th>ADMINISTRATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cetirizine</td>
<td>10mg</td>
<td>PO</td>
<td></td>
<td></td>
<td></td>
<td>Date Time Sign</td>
</tr>
<tr>
<td>Chlorphenamine</td>
<td>10mg</td>
<td>IV</td>
<td></td>
<td></td>
<td></td>
<td>Date Time Sign</td>
</tr>
<tr>
<td>Hydrocortisone</td>
<td>100mg</td>
<td>IV</td>
<td></td>
<td></td>
<td></td>
<td>Date Time Sign</td>
</tr>
<tr>
<td>Salbutamol</td>
<td>5mg</td>
<td>Nebs</td>
<td></td>
<td></td>
<td></td>
<td>Date Time Sign</td>
</tr>
<tr>
<td>Adrenaline Auto-Injector</td>
<td>500mcg</td>
<td>IM</td>
<td></td>
<td></td>
<td></td>
<td>Date Time Sign</td>
</tr>
</tbody>
</table>

Compiled by: Date: 19 Aug 2019... Approved by: Date: 02 Sep 2019...
23. **Appendix 4.5: Alternative dosing schedule for low risk patients** (e.g. those who are suitable for direct oral challenge test without prior skin testing)

1. Perform a set of baseline observations (BP, Pulse, Sp02) and document

2. Administer 100% of the standard dose of the test drug (e.g. usual dose of Amoxicillin or penicillin V = 500mg) and document.

3. Ask the patient to report any adverse reaction (Appendix 1), monitor for 30 minutes and perform a set of observations (BP, Pulse, Sp02) and document.

4. Monitor for a further 30 minutes, ask the patient to report any adverse reactions (Appendix 1) and perform a set of observations (BP, Pulse, Sp02) and document.

**Appendix 4.6 Alternative dosing schedule (to be used if indicated after discussion with a consultant immunologist)**

1. Administer 1% of the standard dose of the test drug (e.g. usual dose of amoxicillin or penicillin V = 500mg - start with 5mg) and document.

2. Ask the patient to report any adverse reaction (Appendix 1), monitor for 15-20 minutes and perform a set of observations (BP, Pulse, Sp02) and document.

3. If no reaction or significant change in observations then administer further 10% of the standard dose of the test drug (e.g. 50mg of amoxicillin or penicillin V when the standard dose is 500mg) and document.

4. Ask the patient to report any adverse reaction (Appendix 1), monitor for 15-20 minutes and perform a set of observations (BP, Pulse, Sp02) and document.

5. If no reaction or significant change in observations then administer further 50% of the standard dose of the test drug (e.g. 250mg of amoxicillin or penicillin V when the standard dose is 500mg) and document.
6. If no reaction or significant change in observations then administer the final standard dose (500mg of amoxicillin or penicillin V) and document.

BIBLIOGRAPHY: